RT Journal Article
SR Electronic
T1 High-resolution longitudinal serum proteome trajectories in COVID-19 reveal patients-specific seroconversion
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.22.21252236
DO 10.1101/2021.02.22.21252236
A1 Philipp E. Geyer
A1 Florian M. Arend
A1 Sophia Doll
A1 Marie-Luise Louiset
A1 Sebastian Virreira Winter
A1 Johannes B. Müller-Reif
A1 Furkan M. Torun
A1 Michael Weigand
A1 Peter Eichhorn
A1 Mathias Bruegel
A1 Maximilian T. Strauss
A1 Lesca M. Holdt
A1 Matthias Mann
A1 Daniel Teupser
YR 2021
UL http://medrxiv.org/content/early/2021/02/23/2021.02.22.21252236.abstract
AB Biomarkers for COVID-19 are urgently needed. Here we bring the powerful technology of mass spectrometry (MS)-based proteomics to bear on this challenge. We measured serum proteomes of COVID-19 patients and symptomatic, but PCR-negative controls, in a time-resolved manner. In 262 controls and 458 longitudinal samples (average of 31 days) of 31 patients, hospitalized for COVID-19, a remarkable 26% of proteins changed significantly. Bioinformatics analyses revealed co-regulated groups and shared biological functions. Proteins of the innate immune system such as CRP, SAA1, CD14, LBP and LGALS3BP decreased early in the time course. In contrast, regulators of coagulation (APOH, FN1, HRG, KNG1, PLG) and lipid homeostasis (APOA1, APOC1, APOC2, APOC3, PON1) increased over the course of the disease. A global correlation map provides a systems-wide functional association between proteins, biological processes and clinical chemistry parameters. Importantly, five SARS-CoV-2 immunoassays against antibodies revealed excellent correlations with an extensive range of immunoglobulin regions, which were quantified by MS-based proteomics. The high-resolution profile of all immunoglobulin regions showed individual-specific differences and commonalities of potential pathophysiological relevance.HighlightsA total of 720 proteomes of 262 symptomatic controls and 458 longitudinal samples (average 31 days) of hospitalized COVID-19 cases were analyzed26% of the 502 quantified proteins significantly changed in COVID-19 patientsThe innate immune and the coagulation system were strongly regulatedMS-based profiles of immunoglobulin regions allow the detection of seroconversion in a highly detailed fashion on the patient levelITIH4 may be a prospective marker of COVID-19 mortalityCompeting Interest StatementPEG, SVW, SD, MTS, FMT and JBMR are employees of OmicEra Diagnostics GmbH.Funding StatementThe work carried out in this project was funded by OmicEra Diagnostics GmbH and the University Hospital of LMU Munich, and supported by the German Federal Ministry of Education and Research (BMBF) project ProDiag (grant numbers: 01KI20377A, 01KI20377B) and the German Biobank Alliance, Munich (01EY1711C).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Anonymized analysis has been approved by the Ethics Committee of LMU Munich (reference number 21-0047).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be uploaded to the PRIDE ProteomeXchange consortia